A multikinase inhibitor used in the second-line setting for hepatocellular carcinoma offers limited increases in quality-adjusted life years. READ MORE
A multikinase inhibitor used in the second-line setting for hepatocellular carcinoma offers limited increases in quality-adjusted life years.
The US Food and Drug Administration has indicated nivolumab for intravenous use in patients with previously treated liver cancer.
Individualizing radiotherapy according to levels of a patient-specific biomarker of liver function safely achieves local control in cancer patients at high risk for liver damage.
Death rates from liver cancer in the US have doubled since the 1980s and continue to rise, largely due to risk factors like hepatitis that should be the focus of better treatment and prevention efforts.
Research in Review
A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years at a significantly high cost.
Researchers aimed to evaluate the safety, utilization, and cost of percutaneous liver biopsy over the last 10 years in a study published in Cancer Investigation.